0.88
7.40%
+0.0606
Cytosorbents Corp stock is currently priced at $0.88, with a 24-hour trading volume of 109.33K.
It has seen a +7.40% increased in the last 24 hours and a -4.82% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.8317 pivot point. If it approaches the $0.9082 resistance level, significant changes may occur.
Previous Close:
$0.8194
Open:
$0.82
24h Volume:
109.33K
Market Cap:
$47.79M
Revenue:
$31.09M
Net Income/Loss:
$-28.51M
P/E Ratio:
-1.4667
EPS:
-0.6
Net Cash Flow:
$-22.59M
1W Performance:
+7.45%
1M Performance:
-4.82%
6M Performance:
-38.03%
1Y Performance:
-68.12%
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
732-329-8885
Address
7 Deer Park Drive, Suite K, Monmouth Junction, NJ
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-07-23 | Initiated | B. Riley Securities | Buy |
Oct-14-21 | Resumed | B. Riley Securities | Buy |
Sep-17-20 | Initiated | Jefferies | Buy |
Sep-01-20 | Initiated | SVB Leerink | Outperform |
Aug-08-17 | Reiterated | Maxim Group | Buy |
Oct-26-16 | Initiated | Aegis Capital | Buy |
May-24-16 | Initiated | Maxim Group | Buy |
Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
May-12-15 | Reiterated | MLV & Co | Buy |
Apr-01-15 | Reiterated | MLV & Co | Buy |
Mar-05-15 | Initiated | MLV & Co | Buy |
Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
GlobeNewswire Inc.
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
GlobeNewswire Inc.
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
GlobeNewswire Inc.
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
GlobeNewswire Inc.
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
GlobeNewswire Inc.
What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents
Benzinga
Cytosorbents Corp Stock (CTSO) Financials Data
Cytosorbents Corp (CTSO) Revenue 2024
CTSO reported a revenue (TTM) of $31.09 million for the quarter ending December 31, 2023, a +5.88% rise year-over-year.
Cytosorbents Corp (CTSO) Net Income 2024
CTSO net income (TTM) was -$28.51 million for the quarter ending December 31, 2023, a +13.12% increase year-over-year.
Cytosorbents Corp (CTSO) Cash Flow 2024
CTSO recorded a free cash flow (TTM) of -$22.59 million for the quarter ending December 31, 2023, a +34.88% increase year-over-year.
Cytosorbents Corp (CTSO) Earnings per Share 2024
CTSO earnings per share (TTM) was -$0.64 for the quarter ending December 31, 2023, a +14.67% growth year-over-year.
About Cytosorbents Corp
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Cap:
|
Volume (24h):